Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemiaIomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemiaNEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the devel ...

Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout. However, if they fail, that may mean the end of the road for these companies. Here is a list of promising biotechs priced under $10 that could offer a huge return on investment in the coming months.Actinium Pharmaceuticals (ATNM)Source: ShutterstockActinium Pharmaceuticals (NYSEMKT:ATNM) is a biotech working on targe ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Actinium Pharmaceuticals (ATNM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Actinium Pharmaceuticals is a member of our Medical group, which includes 1042 different companies and currently sits at #6 in the ...

PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). The report said: "Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biolo ...

Market Overview - The Acute Myeloid Leukemia (AML) market was valued at USD 2.1 billion in 2023 and is projected to grow at a CAGR of 10.7% from 2024 to 2032, driven by advancements in research, government initiatives, and increasing prevalence of AML [1][2] - In 2023, there were approximately 20,380 new cases of AML reported in the U.S., indicating a rising patient pool due to an aging population [1] Treatment Segments - The chemotherapy segment generated the largest market revenue of USD 1.3 billion in 2023, as it effectively targets rapidly dividing AML cells [2] - Approximately 60-70% of adults with AML can expect to achieve complete remission after appropriate chemotherapy, highlighting its efficacy [2] Company Developments - Actinium Pharmaceuticals presented preclinical data at the 2024 EHA Congress showing that Actimab-A in combination with menin inhibitors significantly enhances AML cell death compared to monotherapy [3][4] - Actimab-A targets CD33, a marker prevalent in AML patients, and is designed for combination therapies with other agents, including chemotherapy and targeted therapies [5][6] Menin Inhibitors - Menin inhibitors are being developed for AML patients with KMT2A rearrangements and NPM1 mutations, which affect approximately 10% and 30% of AML patients, respectively [6] - Revumenib and ziftomenib are notable menin inhibitors, with revumenib expected to have PDUFA data by September 2024 and ziftomenib currently in a registration Phase 2 trial [6][7] Clinical Trials and Future Prospects - Kura Oncology has completed enrollment for its Phase 2 trial of ziftomenib in relapsed or refractory NPM1-mutant AML, with topline data expected in early 2025 [7][8] - The combination of Actimab-A with menin inhibitors shows promise for improving treatment outcomes across various AML settings, including frontline and relapsed cases [6][8]

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiot ...

-  Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial-  Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trialNEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Comp ...

- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and venetoclax treated patients - SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination NEW YORK, June 11, 2 ...

Core Insights - The article discusses the impact of positive news on stock prices during meme stock rallies, highlighting the case of Novavax, which saw a 328% increase in stock price after partnering with Sanofi [1]. Group 1: Biotech Stocks in Meme Frenzy - Biotech stocks are favored during meme stock rallies, particularly those in clinical trials, as positive news can significantly boost stock prices [1]. - Atossa Therapeutics (NASDAQ:ATOS) is developing oncology medicines and has a bullish trend with a year-to-date upside of nearly 50%. The company is working on (Z)-endoxifen, which has potential across various breast cancer treatments [3][4]. - Entera Bio (NASDAQ:ENTX) focuses on orally delivered peptide and protein therapeutics, with a 137% stock surge in the last year. Its lead candidate, EB613, targets high-risk post-menopausal osteoporosis, a market affecting 200 million women globally [5][6]. - Actinium Pharmaceuticals (NYSE:ATNM) is developing targeted radiotherapies, with its Iomab-B in phase three trials showing positive data. The company is expected to file for regulatory approval in the second half of 2024 [7]. Group 2: Upcoming Catalysts and Financial Position - Atossa Therapeutics has clinical trial data expected in the second half of 2024, which could lead to a significant stock rally [4]. - Entera Bio is preparing for a Phase three study for EB613, pending FDA qualification of a quantitative BMD endpoint by January 2025, which could act as a catalyst for stock price increase [6]. - Actinium Pharmaceuticals has a solid cash buffer to fund operations into the second half of 2026, indicating no immediate financial concerns [7].

-  KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar -  Webinar to be held on Monday, May 20th at 8:00 AM ET NEW YORK, May 15, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL webinar on M ...